Clinical Trials
57 trialsNCT07557914 2026-06-03
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
First Hospital of China Medical University
Phase 2 Not yet recruiting
NCT07495579 2026-05-27
REVIVE
Asan Medical Center
Phase 2 Not yet recruiting
NCT07586046 2026-05-14
MARGIN
Northwestern University
Phase 2 Not yet recruiting
NCT07584018 2026-05-13
The DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07226063 2026-05-05
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07565415 2026-05-04
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT04172779 2026-05-01
ECHO-B
University of Texas Southwestern Medical Center
Phase 2 Not yet recruiting
NCT07543783 2026-04-28
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT07537777 2026-04-17
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT07537972 2026-04-17
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Phase 2 Not yet recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT07515469 2026-04-07
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT07381634 2026-03-11
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07463248 2026-03-11
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
West China Hospital
Phase 2 Not yet recruiting
NCT07412054 2026-02-17
BLP-HCC
Fudan University
Phase 2 Not yet recruiting
NCT07363512 2026-01-23
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT07314372 2026-01-20
FAD-HCC-001
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Not yet recruiting
NCT07324473 2026-01-07
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
First Affiliated Hospital of Chongqing Medical University
Phase 2 Not yet recruiting
NCT07179900 2025-12-11
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT07239986 2025-11-20
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
Broadenbio Ltd., Co.
Phase 2 Not yet recruiting
NCT07209813 2025-10-07
GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma
Beijing Gene Key Life Technology Co., Ltd
Phase 2 Not yet recruiting
NCT07192848 2025-09-25
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 2 Not yet recruiting
NCT07157306 2025-09-05
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07151326 2025-09-03
CAPIO
National Health Research Institutes, Taiwan
Phase 2 Not yet recruiting
NCT07150377 2025-09-02
A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT07131501 2025-08-20
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07128251 2025-08-17
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Anhui Provincial Hospital
Phase 2 Not yet recruiting
NCT07078305 2025-07-22
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07064668 2025-07-15
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
Tongji Hospital
Phase 2 Not yet recruiting
NCT06954116 2025-06-13
CCGLC-017
Tongji Hospital
Phase 2 Not yet recruiting
NCT06984718 2025-05-22
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
Akeso
Phase 2 Not yet recruiting
NCT06958484 2025-05-06
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
The Affiliated Hospital of Xuzhou Medical University
Phase 2 Not yet recruiting
NCT06900478 2025-03-28
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06884982 2025-03-19
An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib
Northern Jiangsu People's Hospital
Phase 2 Not yet recruiting
NCT05195294 2025-03-10
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
Lion TCR Pte. Ltd.
Phase 2 Not yet recruiting
NCT06867432 2025-03-10
Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06724263 2024-12-09
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
Tasly Biopharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT06685354 2024-11-12
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06592612 2024-09-19
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06546280 2024-08-09
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
Zhujiang Hospital
Phase 2 Not yet recruiting
NCT06538935 2024-08-06
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06535737 2024-08-02
CPAB
Chulalongkorn University
Phase 2 Not yet recruiting
NCT06530784 2024-07-31
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06512467 2024-07-22
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06482008 2024-07-01
HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06475287 2024-06-26
HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Not yet recruiting
NCT06375317 2024-04-19
HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure
Fudan University
Phase 2 Not yet recruiting